Clinical Trial Registry Errors Undermine Transparency
Clinical Trial Registry Errors Undermine Transparency
A lack of comprehension among some researchers about how to use ClinicalTrials.gov may be hindering public access to trial information and holding up drug study results, an investigation by The Scientist finds.
A lack of comprehension among some researchers about how to use ClinicalTrials.gov may be hindering public access to trial information and holding up drug study results, an investigation by The Scientist finds.
fluvoxamine
What’s the Evidence for Fluvoxamine in COVID-19?
Catherine Offord | May 20, 2022 | 7 min read
The US FDA’s decision not to grant an emergency use authorization for the antidepressant as a COVID-19 treatment highlights a lack of consensus among researchers about how to interpret clinical data on the drug.
A Closer Look at the New Fluvoxamine Trial Data
Catherine Offord | Nov 2, 2021 | 8 min read
Authors of a newly published study on the use of an antidepressant for COVID-19 claim the drug greatly reduces hospitalizations and mortality. But some experts question whether that’s really what the data show.